PMID- 23580820
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130415
LR  - 20211021
IS  - 0971-5851 (Print)
IS  - 0975-2129 (Electronic)
IS  - 0971-5851 (Linking)
VI  - 33
IP  - 4
DP  - 2012 Oct
TI  - Stem cell transplant: An experience from eastern India.
PG  - 203-9
LID - 10.4103/0971-5851.107078 [doi]
AB  - BACKGROUND: Hematopoietic stem cell transplant using human leukocyte antigen 
      (HLA)-matched sibling or unrelated bone marrow, or related or unrelated cord 
      blood has been performed successfully to treat patients with different types of 
      hematological malignancies, genetic disorders and hereditary immune deficiencies. 
      Since 1983, stem cell transplantation has been carried out in different 
      institutes of India. But, till then, no transplantation was performed in eastern 
      India. MATERIALS AND METHODS: Our present study is reporting for the first time 
      stem cell transplantation in eastern India. From August 2000 to June 2011 (with a 
      3-year gap for up-gradation), we have performed a total of 22 transplants. 
      Thirteen patients (M:F:9:4) with indications of aplastic anemia, thalassaemia, 
      acute myeloid leukemia and chronic myeloid leukemia underwent allogenic 
      transplant, whereas autologous transplant was performed for nine patients 
      (M:F:2:1) of multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma and 
      neuroblastoma. The median age of the patients was 19.6 years, with a range of 5 
      years 8 months to 52 years. Fourteen patients received myeloablative conditioning 
      regime whereas eight patients received immunosuppressive and less myeloablative 
      protocol. Sources of stem cells in case of allogenic transplant are bone marrow 
      and related or unrelated umbilical cord blood and in case of autologous 
      transplant, these are peripheral blood stem cells or self-bone marrow. Standard 
      prophylactic medication was followed prior to transplants. RESULTS: A 
      disease-free survival of 68.18% and overall survival of 86.3% were seen at the 
      median follow-up period of 4.6 years. Common post-transplant complications were 
      mucositis, infection, venoocclusive disease, graft versus host disease, 
      hemorrhagic cystitis, etc. CONCLUSION: The use of cord blood as a source of stem 
      cells has been proved inferior as compared with the bone marrow stem cell source 
      in cases of thalassaemia in our institute and thus is not recommended for 
      thalassaemia. But, it has been proved to be a very useful and effective stem cell 
      source (both related and unrelated cord blood) in cases of aplastic anemia and 
      other immunological disorders.
FAU - Mukhopadhyay, A
AU  - Mukhopadhyay A
AD  - Department of Haemato-Oncology, Molecular Biology and Bone Marrow Transplant 
      Unit, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, West Bengal, 
      India.
FAU - Gupta, P
AU  - Gupta P
FAU - Basak, J
AU  - Basak J
FAU - Chakraborty, A
AU  - Chakraborty A
FAU - Bhattacharyya, D
AU  - Bhattacharyya D
FAU - Mukhopadhyay, S
AU  - Mukhopadhyay S
FAU - Roy, U K
AU  - Roy UK
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Indian J Med Paediatr Oncol
JT  - Indian journal of medical and paediatric oncology : official journal of Indian 
      Society of Medical & Paediatric Oncology
JID - 9604571
PMC - PMC3618641
OTO - NOTNLM
OT  - Aplastic anemia
OT  - bone marrow transplantation
OT  - cord blood transplantation
OT  - eastern Indian data
OT  - stem cell transplantation
OT  - thalassaemia
COIS- Conflict of Interest: None declared.
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:01
PMCR- 2012/10/01
CRDT- 2013/04/13 06:00
PHST- 2013/04/13 06:00 [entrez]
PHST- 2013/04/13 06:00 [pubmed]
PHST- 2013/04/13 06:01 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - IJMPO-33-203 [pii]
AID - 10.4103/0971-5851.107078 [doi]
PST - ppublish
SO  - Indian J Med Paediatr Oncol. 2012 Oct;33(4):203-9. doi: 10.4103/0971-5851.107078.